电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

HBSAg 抗体

HBsAg 适用: Virus, 人, 小鼠 ELISA, WB, IF (cc), IF (p), IHC (p), IHC (fro) 宿主: 山羊 Polyclonal unconjugated
产品编号 ABIN731303
发货至: 中国
  • 抗原 See all HBSAg (HBsAg) 抗体
    HBSAg (HBsAg) (Hepatitis B Virus Surface Antigen (HBsAg))
    适用
    • 103
    • 30
    • 20
    • 17
    • 3
    • 1
    • 1
    Virus, 人, 小鼠
    宿主
    • 67
    • 33
    • 28
    • 3
    山羊
    克隆类型
    • 67
    • 57
    多克隆
    标记
    • 82
    • 16
    • 12
    • 10
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This HBSAg antibody is un-conjugated
    应用范围
    • 86
    • 35
    • 20
    • 15
    • 15
    • 12
    • 12
    • 10
    • 7
    • 6
    • 6
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
    交叉反应
    人, 小鼠, Virus
    预测反应
    Bee
    纯化方法
    Purified by Protein A.
    免疫原
    Human Hepatitis B Surface Antigen
    亚型
    IgG
    Top Product
    Discover our top product HBsAg Primary Antibody
  • 应用备注
    WB 1:300-5000
    ELISA 1:500-1000
    IHC-P 1:200-400
    IHC-F 1:100-500
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    限制
    仅限研究用
  • 状态
    Liquid
    浓度
    1 μg/μL
    缓冲液
    Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    储存液
    ProClin
    注意事项
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    储存条件
    -20 °C
    储存方法
    Store at -20°C for 12 months.
    有效期
    12 months
  • Andriamandimby, Olive, Shimakawa, Rakotomanana, Razanajatovo, Andrianinarivomanana, Ravalohery, Andriamamonjy, Rogier, Héraud: "Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy." in: BMC public health, Vol. 17, Issue 1, pp. 636, (2018) (PubMed).

    Sakurai, Mitani, Yamamoto, Takayama, Tachibana, Watashi, Wakita, Iijima, Tanaka, Mizuguchi: "Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection." in: Scientific reports, Vol. 7, pp. 45698, (2017) (PubMed).

    Nakabori, Hikita, Murai, Nozaki, Kai, Makino, Saito, Tanaka, Wada, Eguchi, Takahashi, Suemizu, Sakamori, Hiramatsu, Tatsumi, Takehara: "Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver." in: Scientific reports, Vol. 6, pp. 27782, (2016) (PubMed).

    Ito, Ando, Nakamura, Ishida, Kanbe, Kobiyama, Yamamoto, Ishii, Hara, Seishima, Ishikawa: "Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand." in: Journal of viral hepatitis, (2016) (PubMed).

    Yu, Wang, Tian, Wang, Li, Yuan, Chen, Li, Zhuang, Ling: "Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice." in: Vaccine, Vol. 34, Issue 50, pp. 6276-6284, (2016) (PubMed).

    Lai, Liang, Lin, Huang, Huang, Chen, Yeh: "Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation." in: Oncogenesis, Vol. 5, Issue 12, pp. e273, (2016) (PubMed).

    Watanabe, Hamada-Tsutsumi, Yokomaku, Imamura, Sugiura, Tanaka: "Postexposure Prophylactic Effect of Hepatitis B Virus (HBV)-Active Antiretroviral Therapy against HBV Infection." in: Antimicrobial agents and chemotherapy, Vol. 59, Issue 2, pp. 1292-8, (2015) (PubMed).

    Okumura, Ikeda, Satoh, Dansako, Sugiyama, Mizokami, Kato: "Negative regulation of hepatitis B virus replication by forkhead box protein A in human hepatoma cells." in: FEBS letters, Vol. 589, Issue 10, pp. 1112-8, (2015) (PubMed).

    Ma, Song, Teng, Fu, Hao, Chen, Xu, Gu: "Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant." in: Archives of virology, Vol. 158, Issue 4, pp. 785-91, (2013) (PubMed).

    Xiang, Wei, Lei, Liu, Liu, Guo: "A simple and rapid capillary chemiluminescence immunoassay for quantitatively detecting human serum HBsAg." in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Vol. 32, Issue 12, pp. 1557-64, (2013) (PubMed).

    Gong, Liu, Dong, Zhou, Li et al.: "Construction and expression of a recombinant eukaryotic expression plasmid containing the preS1-preS2-S genes of hepatitis B virus and the granulocyte-macrophage colony stimulating factor gene: A ..." in: Biomedical reports, Vol. 1, Issue 2, pp. 251-256, (2013) (PubMed).

  • 抗原
    HBSAg (HBsAg) (Hepatitis B Virus Surface Antigen (HBsAg))
    别名
    HBsAg (HBsAg 产品)
    物质类
    Viral Protein
    背景

    Synonyms: HBsAg, HBV major surface antigen, HBV surface antigen, Hepatitis B Virus major surface antigen, Major surface antigen, S, Human Hepatitis B Surface Antigen

    Background: Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.

    UniProt
    Q67926
You are here:
客服